Nurix Therapeutics (NRIX) Net Equity Issued and Repurchased (2020 - 2026)

Nurix Therapeutics' (NRIX) quarterly Net Equity Issued and Repurchased came in at $18.0 million in Q1 2026, down 81.13% on a QoQ basis from $95.4 million in Q4 2024.

Nurix Therapeutics (NRIX) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends

Nurix Therapeutics (NRIX) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $18.0 million in Q1 2026.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $18.0 million in Q1 2026; TTM through May 2026 was $18.0 million, a 86.98% decrease from a year earlier, with the FY2024 full-year figure at $289.8 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased for Q1 2026 stood at $18.0 million, down from $95.4 million in the prior quarter.
  • Over the last five years, Net Equity Issued and Repurchased for NRIX reached as high as $95.4 million in Q4 2024 and fell as low as $18.0 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Nurix Therapeutics 2.64 Bn 2.19 Bn - -

Historic Data

Download Data
DateValue
Feb 28, 2026 18.00 Mn
Feb 28, 2026 18.00 Mn
Nov 30, 2024 95.40 Mn
Nov 30, 2024 95.40 Mn
Aug 31, 2024 42.90 Mn
Aug 31, 2024 42.90 Mn
May 31, 2024 50.20 Mn
May 31, 2024 50.20 Mn
May 31, 2021 -43,000.00
May 31, 2021 -43,000.00
Nov 30, 2020 -99.39 Mn
Nov 30, 2020 -99.39 Mn
Aug 31, 2020 99.39 Mn
Aug 31, 2020 99.39 Mn
May 31, 2020 14,000.00
May 31, 2020 14,000.00